Cost-effectiveness of atezolizumab plus chemotherapy as first-line therapy for metastatic urothelial cancer
S Qin, L Yi, S Li, C Tan, X Zeng, L Wang, Y Peng… - Advances in …, 2021 - Springer
Abstract Introduction The IMvigor130 trial found that atezolizumab plus platinum-based
chemotherapy (atezolizumab group) as first-line therapy prolonged progression-free survival …
chemotherapy (atezolizumab group) as first-line therapy prolonged progression-free survival …
Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer
S Qin, L Yi, S Li, C Tan, X Zeng, L Wang… - Advances in …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction The IMvigor130 trial found that atezolizumab plus platinum-based
chemotherapy (atezolizumab group) as first-line therapy prolonged progression-free survival …
chemotherapy (atezolizumab group) as first-line therapy prolonged progression-free survival …
Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.
S Qin, L Yi, S Li, C Tan, X Zeng, L Wang… - Advances in …, 2021 - europepmc.org
Methods A Markov model was adopted to compare the cost and effectiveness of
atezolizumab and placebo group in the first-line setting of patients with mUC. Life years …
atezolizumab and placebo group in the first-line setting of patients with mUC. Life years …